우울증 신규 치료법 보고서(2026년)(2분기판)

The Global Depression Emerging Therapies Market is set to reach USD 1.97 billion in 2035, growing at a CAGR of 9.2% from USD 0.89 billion in 2026.

Depression remains one of the most common and disabling mental health disorders worldwide, affecting hundreds of millions of individuals and contributing substantially to healthcare costs, disability, and reduced quality of life. Although conventional antidepressants remain the standard of care, delayed onset of action, incomplete response, relapse, and treatment resistance continue to create significant unmet medical needs. Emerging therapies are increasingly targeting glutamatergic signaling, neuroplasticity, inflammation, neuropeptides, and other non-monoaminergic pathways to improve efficacy and accelerate symptom relief.

Market Drivers

Rising Global Burden of Depression

The increasing prevalence of major depressive disorder, growing awareness of mental health, improved diagnosis, and expanding access to psychiatric services continue to drive demand for innovative therapies. Depression remains one of the leading contributors to disability worldwide, creating significant opportunities for therapeutic innovation.

Growing Focus on Treatment-Resistant Depression

A substantial proportion of patients fail to achieve remission with conventional antidepressants, increasing demand for therapies with novel mechanisms of action. Pharmaceutical companies are actively developing treatments designed specifically for treatment-resistant depression and severe depressive disorders.

Expansion of Novel Therapeutic Approaches

Research into psychedelic-assisted therapies, ketamine derivatives, neurostimulation, neuroimmune modulation, and precision psychiatry is expanding rapidly. These approaches offer the potential for faster onset of action and improved outcomes compared with traditional monoaminergic antidepressants.

Advances in Precision Psychiatry

Artificial intelligence, digital biomarkers, genetics, and biomarker-guided patient selection are improving clinical trial efficiency while supporting personalized treatment strategies for depression.

Market Restraints

High Clinical Development Risk

Psychiatric drug development remains challenging because of placebo response, disease heterogeneity, subjective clinical endpoints, and complex neurobiology. These factors contribute to lengthy development timelines and relatively high failure rates.

Regulatory Complexity

Novel therapies including psychedelics, regenerative approaches, and neuromodulation technologies require extensive clinical validation and long-term safety data before widespread commercialization.

Reimbursement and Access Challenges

Premium-priced innovative therapies may face reimbursement limitations until sufficient evidence demonstrates long-term clinical and economic value.

Emerging Therapy and Technology Insights

The global depression emerging therapies market can be segmented by development phase, disease indication, therapeutic approach, route of administration, and geography.

By development phase, the market includes discovery and preclinical research, Phase I, Phase II, Phase III, and regulatory review. Early-stage research continues to represent a significant portion of the pipeline, while numerous late-stage candidates are progressing toward commercialization.

By disease indication, development programs target major depressive disorder, treatment-resistant depression, bipolar depression, postpartum depression, and other depressive disorders. Major depressive disorder accounts for the largest share of ongoing research because of its high global disease burden.

By therapeutic approach, emerging therapies include glutamatergic modulators, psychedelic-assisted therapies, neuropeptide-based therapies, anti-inflammatory therapies, neurostimulation technologies, gene-targeted therapies, and combination treatments. Glutamatergic therapies and psychedelic compounds remain among the fastest-growing areas of innovation because of their rapid antidepressant effects demonstrated in clinical studies.

By route of administration, investigational therapies include oral therapies, intravenous therapies, intranasal therapies, injectable biologics, and device-based interventions. Intranasal and rapid-acting therapies continue to receive significant attention because they offer faster symptom relief for patients with severe depression.

Technological innovation continues through artificial intelligence, digital biomarkers, pharmacogenomics, wearable monitoring technologies, digital therapeutics, and precision medicine, enabling improved patient selection and individualized treatment strategies.

Emerging Therapy Trends

The depression therapeutic landscape continues to evolve toward personalized and mechanism-based treatments.

Key trends include:

• Expansion of rapid-acting antidepressants.
• Increasing development of psychedelic-assisted therapies.
• Growing investment in glutamatergic pathway modulation.
• Wider adoption of precision psychiatry.
• Expansion of biomarker-guided clinical trials.
• Increased use of artificial intelligence in drug development.
• Greater integration of neuromodulation and digital therapeutics.

Regional Insights

North America remains the leading market for emerging depression therapies because of strong pharmaceutical innovation, advanced clinical research infrastructure, favorable regulatory support, and significant investment in mental health research.

Europe continues to strengthen its position through collaborative neuroscience research, increasing mental health awareness, and expanding clinical development programs.

Asia-Pacific is expected to experience the fastest growth owing to improving mental healthcare infrastructure, rising diagnosis rates, expanding pharmaceutical research, and increasing healthcare expenditure across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually expanding psychiatric care infrastructure and participation in multinational clinical trials, creating new opportunities for emerging therapies.

Competitive Landscape

The depression emerging therapies landscape includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, neuroscience startups, and contract research organizations.

Organizations continue investing in novel antidepressants, psychedelic therapies, glutamatergic compounds, neuroimmune therapies, digital therapeutics, artificial intelligence, and precision psychiatry. Strategic collaborations, licensing agreements, mergers and acquisitions, and research partnerships remain central to accelerating innovation and commercialization.

Future Outlook

The future of depression treatment will be shaped by rapid advances in neuroscience, precision medicine, pharmacogenomics, artificial intelligence, and novel biological targets. Continued progress in rapid-acting antidepressants, psychedelic-assisted therapies, digital mental health technologies, and biomarker-guided treatment is expected to significantly improve patient outcomes while expanding commercial opportunities through 2035.

Conclusion

The Global Depression Emerging Therapies Market is positioned for significant expansion through 2035, supported by increasing research investment, growing unmet medical needs, and continuous innovation in psychiatric drug development. Although clinical complexity, regulatory requirements, and reimbursement challenges remain, advances in rapid-acting therapies, precision psychiatry, and novel mechanisms of action are expected to reshape depression treatment and create substantial opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, and investors.

Key Benefits of this Report

• Comprehensive analysis of the global depression emerging therapies landscape.
• Detailed evaluation of investigational therapies, pipeline maturity, and development trends.
• Competitive assessment of innovation strategies and commercialization opportunities.
• Insights into precision psychiatry, novel mechanisms of action, and future treatment trends.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, investors, researchers, consultants, and policymakers.

What Businesses Use Our Reports For

Pipeline assessment, competitive intelligence, clinical development planning, licensing and partnership evaluation, commercialization strategy, investment analysis, regulatory planning, portfolio optimization, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global depression emerging therapies landscape by development phase, disease indication, therapeutic approach, route of administration, and geography
• Evaluation of investigational therapies, clinical development progress, pipeline maturity, regulatory developments, and commercialization opportunities
• Assessment of strategic collaborations, licensing agreements, mergers and acquisitions, competitive positioning, and innovation trends
• Analysis of rapid-acting antidepressants, glutamatergic therapies, psychedelic-assisted therapies, neurostimulation technologies, precision psychiatry, digital therapeutics, biomarker-guided treatment approaches, and future therapeutic opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Emerging Therapies Market Overview
• 1.3 Key Findings
• 1.4 Pipeline Highlights
• 1.5 Innovation Trends
• 1.6 Key Developers and Sponsors
• 1.7 Unmet Needs Assessment
• 1.8 Future Outlook

2. Depression Disease Overview

• 2.1 Introduction to Depression
• 2.2 Disease Classification
  • 2.2.1 Major Depressive Disorder (MDD)
  • 2.2.2 Treatment-Resistant Depression (TRD)
  • 2.2.3 Persistent Depressive Disorder (Dysthymia)
  • 2.2.4 Postpartum Depression
  • 2.2.5 Seasonal Affective Disorder
  • 2.2.6 Adolescent Depression
  • 2.2.7 Geriatric Depression
• 2.3 Disease Pathophysiology
• 2.4 Neurobiological Mechanisms
• 2.5 Current Treatment Landscape
• 2.6 Limitations of Existing Therapies
• 2.7 Unmet Clinical Needs

3. Emerging Therapies Market Overview

• 3.1 Evolution of Depression Therapeutics
• 3.2 Innovation Landscape Assessment
• 3.3 Emerging Treatment Modalities
• 3.4 Research and Development Trends
• 3.5 Investment and Funding Trends
• 3.6 Future Treatment Paradigm Evolution

4. Pipeline Landscape Analysis

• 4.1 Pipeline Overview
• 4.2 Pipeline by Development Phase
  • 4.2.1 Discovery Stage
  • 4.2.2 Preclinical Stage
  • 4.2.3 Phase I
  • 4.2.4 Phase II
  • 4.2.5 Phase III
  • 4.2.6 Registration Stage
• 4.3 Pipeline by Molecule Type
  • 4.3.1 Small Molecules
  • 4.3.2 Neuroactive Steroids
  • 4.3.3 Biologics
  • 4.3.4 Psychedelic Compounds
  • 4.3.5 Gene and RNA-Based Therapies
• 4.4 Pipeline by Route of Administration
  • 4.4.1 Oral
  • 4.4.2 Intranasal
  • 4.4.3 Intravenous
  • 4.4.4 Injectable
• 4.5 Pipeline by Disease Type
  • 4.5.1 Major Depressive Disorder
  • 4.5.2 Treatment-Resistant Depression
  • 4.5.3 Postpartum Depression
  • 4.5.4 Other Depression Subtypes

5. Mechanism of Action Analysis

• 5.1 NMDA Receptor Modulators
• 5.2 GABA-A Receptor Modulators
• 5.3 Serotonin Receptor Modulators
• 5.4 Neuroplasticity-Based Therapies
• 5.5 Glutamatergic Pathway Modulators
• 5.6 Inflammation-Modulating Therapies
• 5.7 Psychedelic-Based Therapies
• 5.8 Precision Psychiatry Approaches
• 5.9 Novel CNS Targets

6. Emerging Drug Profiles

• 6.1 AXS-05
  • 6.1.1 Drug Overview
  • 6.1.2 Mechanism of Action
  • 6.1.3 Clinical Development Status
  • 6.1.4 Clinical Trial Results
  • 6.1.5 Competitive Advantages
  • 6.1.6 Future Outlook
• 6.2 COMP360 Psilocybin Therapy
  • 6.2.1 Drug Overview
  • 6.2.2 Mechanism of Action
  • 6.2.3 Clinical Development Status
  • 6.2.4 Clinical Trial Results
  • 6.2.5 Competitive Advantages
  • 6.2.6 Future Outlook
• 6.3 BPL-003
  • 6.3.1 Drug Overview
  • 6.3.2 Mechanism of Action
  • 6.3.3 Clinical Development Status
  • 6.3.4 Clinical Trial Results
  • 6.3.5 Competitive Advantages
  • 6.3.6 Future Outlook
• 6.4 VLS-01
  • 6.4.1 Drug Overview
  • 6.4.2 Mechanism of Action
  • 6.4.3 Clinical Development Status
  • 6.4.4 Clinical Trial Results
  • 6.4.5 Competitive Advantages
  • 6.4.6 Future Outlook
• 6.5 ALTO-100
  • 6.5.1 Drug Overview
  • 6.5.2 Mechanism of Action
  • 6.5.3 Clinical Development Status
  • 6.5.4 Clinical Trial Results
  • 6.5.5 Competitive Advantages
  • 6.5.6 Future Outlook
• 6.6 REL-1017
  • 6.6.1 Drug Overview
  • 6.6.2 Mechanism of Action
  • 6.6.3 Clinical Development Status
  • 6.6.4 Clinical Trial Results
  • 6.6.5 Competitive Advantages
  • 6.6.6 Future Outlook
• 6.7 GH001
  • 6.7.1 Drug Overview
  • 6.7.2 Mechanism of Action
  • 6.7.3 Clinical Development Status
  • 6.7.4 Clinical Trial Results
  • 6.7.5 Competitive Advantages
  • 6.7.6 Future Outlook
• 6.8 CYB003
  • 6.8.1 Drug Overview
  • 6.8.2 Mechanism of Action
  • 6.8.3 Clinical Development Status
  • 6.8.4 Clinical Trial Results
  • 6.8.5 Competitive Advantages
  • 6.8.6 Future Outlook
• 6.9 MM120
  • 6.9.1 Drug Overview
  • 6.9.2 Mechanism of Action
  • 6.9.3 Clinical Development Status
  • 6.9.4 Clinical Trial Results
  • 6.9.5 Competitive Advantages
  • 6.9.6 Future Outlook
• 6.10 EMP-01
  • 6.10.1 Drug Overview
  • 6.10.2 Mechanism of Action
  • 6.10.3 Clinical Development Status
  • 6.10.4 Clinical Trial Results
  • 6.10.5 Competitive Advantages
  • 6.10.6 Future Outlook

7. Clinical Trial Landscape

• 7.1 Clinical Trial Overview
• 7.2 Active Clinical Trials Analysis
• 7.3 Completed Clinical Trials Analysis
• 7.4 Clinical Trial Success Rates
• 7.5 Patient Recruitment Trends
• 7.6 Geographic Distribution of Trials
• 7.7 Key Clinical Milestones
• 7.8 Expected Readouts and Catalysts

8. Competitive Landscape

• 8.1 Emerging Therapy Competitive Assessment
• 8.2 Pipeline Strength Benchmarking
• 8.3 Innovation Leadership Analysis
• 8.4 Strategic Collaborations and Partnerships
• 8.5 Licensing and Co-Development Activities
• 8.6 Mergers and Acquisitions
• 8.7 Competitive Positioning Matrix
• 8.8 Future Competitive Outlook

9. Market Opportunity Assessment

• 9.1 Addressable Patient Population Analysis
• 9.2 Treatment Gap Assessment
• 9.3 Market Potential by Therapy Type
• 9.4 Commercial Opportunity Assessment
• 9.5 Peak Sales Potential Analysis
• 9.6 Adoption Scenario Analysis
• 9.7 Future Revenue Opportunity Outlook

10. Geographical Analysis

• 10.1 North America
  • 10.1.1 Pipeline Activity
  • 10.1.2 Clinical Trial Landscape
  • 10.1.3 Research Infrastructure
  • 10.1.4 Regulatory Environment
  • 10.1.5 Growth Opportunities
• 10.2 Europe
  • 10.2.1 Pipeline Activity
  • 10.2.2 Clinical Trial Landscape
  • 10.2.3 Research Infrastructure
  • 10.2.4 Regulatory Environment
  • 10.2.5 Growth Opportunities
• 10.3 Asia-Pacific
  • 10.3.1 Pipeline Activity
  • 10.3.2 Clinical Trial Landscape
  • 10.3.3 Research Infrastructure
  • 10.3.4 Regulatory Environment
  • 10.3.5 Growth Opportunities
• 10.4 Latin America
  • 10.4.1 Pipeline Activity
  • 10.4.2 Clinical Trial Landscape
  • 10.4.3 Research Infrastructure
  • 10.4.4 Regulatory Environment
  • 10.4.5 Growth Opportunities
• 10.5 Middle East & Africa
  • 10.5.1 Pipeline Activity
  • 10.5.2 Clinical Trial Landscape
  • 10.5.3 Research Infrastructure
  • 10.5.4 Regulatory Environment
  • 10.5.5 Growth Opportunities

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Pipeline Activity
  • 11.1.2 Clinical Trial Landscape
  • 11.1.3 Research Infrastructure
  • 11.1.4 Regulatory Environment
  • 11.1.5 Growth Opportunities
• 11.2 Canada
  • 11.2.1 Pipeline Activity
  • 11.2.2 Clinical Trial Landscape
  • 11.2.3 Research Infrastructure
  • 11.2.4 Regulatory Environment
  • 11.2.5 Growth Opportunities
• 11.3 Germany
  • 11.3.1 Pipeline Activity
  • 11.3.2 Clinical Trial Landscape
  • 11.3.3 Research Infrastructure
  • 11.3.4 Regulatory Environment
  • 11.3.5 Growth Opportunities
• 11.4 United Kingdom
  • 11.4.1 Pipeline Activity
  • 11.4.2 Clinical Trial Landscape
  • 11.4.3 Research Infrastructure
  • 11.4.4 Regulatory Environment
  • 11.4.5 Growth Opportunities
• 11.5 France
  • 11.5.1 Pipeline Activity
  • 11.5.2 Clinical Trial Landscape
  • 11.5.3 Research Infrastructure
  • 11.5.4 Regulatory Environment
  • 11.5.5 Growth Opportunities
• 11.6 Italy
  • 11.6.1 Pipeline Activity
  • 11.6.2 Clinical Trial Landscape
  • 11.6.3 Research Infrastructure
  • 11.6.4 Regulatory Environment
  • 11.6.5 Growth Opportunities
• 11.7 Spain
  • 11.7.1 Pipeline Activity
  • 11.7.2 Clinical Trial Landscape
  • 11.7.3 Research Infrastructure
  • 11.7.4 Regulatory Environment
  • 11.7.5 Growth Opportunities
• 11.8 China
  • 11.8.1 Pipeline Activity
  • 11.8.2 Clinical Trial Landscape
  • 11.8.3 Research Infrastructure
  • 11.8.4 Regulatory Environment
  • 11.8.5 Growth Opportunities
• 11.9 Japan
  • 11.9.1 Pipeline Activity
  • 11.9.2 Clinical Trial Landscape
  • 11.9.3 Research Infrastructure
  • 11.9.4 Regulatory Environment
  • 11.9.5 Growth Opportunities
• 11.10 India
  • 11.10.1 Pipeline Activity
  • 11.10.2 Clinical Trial Landscape
  • 11.10.3 Research Infrastructure
  • 11.10.4 Regulatory Environment
  • 11.10.5 Growth Opportunities
• 11.11 South Korea
  • 11.11.1 Pipeline Activity
  • 11.11.2 Clinical Trial Landscape
  • 11.11.3 Research Infrastructure
  • 11.11.4 Regulatory Environment
  • 11.11.5 Growth Opportunities
• 11.12 Australia
  • 11.12.1 Pipeline Activity
  • 11.12.2 Clinical Trial Landscape
  • 11.12.3 Research Infrastructure
  • 11.12.4 Regulatory Environment
  • 11.12.5 Growth Opportunities

12. Company Profiles

• 12.1 Compass Pathways plc
  • 12.1.1 Overview
  • 12.1.2 Financials
  • 12.1.3 Depression Emerging Therapy Portfolio
  • 12.1.4 Clinical Development Strategy
  • 12.1.5 Key Drug Candidates
  • 12.1.6 Clinical Trial Programs
  • 12.1.7 Strategic Collaborations
  • 12.1.8 Recent Developments
• 12.2 Beckley Psytech Ltd.
  • 12.2.1 Overview
  • 12.2.2 Financials
  • 12.2.3 Depression Emerging Therapy Portfolio
  • 12.2.4 Clinical Development Strategy
  • 12.2.5 Key Drug Candidates
  • 12.2.6 Clinical Trial Programs
  • 12.2.7 Strategic Collaborations
  • 12.2.8 Recent Developments
• 12.3 Alto Neuroscience, Inc.
  • 12.3.1 Overview
  • 12.3.2 Financials
  • 12.3.3 Depression Emerging Therapy Portfolio
  • 12.3.4 Clinical Development Strategy
  • 12.3.5 Key Drug Candidates
  • 12.3.6 Clinical Trial Programs
  • 12.3.7 Strategic Collaborations
  • 12.3.8 Recent Developments
• 12.4 Relmada Therapeutics, Inc.
  • 12.4.1 Overview
  • 12.4.2 Financials
  • 12.4.3 Depression Emerging Therapy Portfolio
  • 12.4.4 Clinical Development Strategy
  • 12.4.5 Key Drug Candidates
  • 12.4.6 Clinical Trial Programs
  • 12.4.7 Strategic Collaborations
  • 12.4.8 Recent Developments
• 12.5 Atai Life Sciences N.V.
  • 12.5.1 Overview
  • 12.5.2 Financials
  • 12.5.3 Depression Emerging Therapy Portfolio
  • 12.5.4 Clinical Development Strategy
  • 12.5.5 Key Drug Candidates
  • 12.5.6 Clinical Trial Programs
  • 12.5.7 Strategic Collaborations
  • 12.5.8 Recent Developments
• 12.6 Cybin Inc.
  • 12.6.1 Overview
  • 12.6.2 Financials
  • 12.6.3 Depression Emerging Therapy Portfolio
  • 12.6.4 Clinical Development Strategy
  • 12.6.5 Key Drug Candidates
  • 12.6.6 Clinical Trial Programs
  • 12.6.7 Strategic Collaborations
  • 12.6.8 Recent Developments
• 12.7 MindMed
  • 12.7.1 Overview
  • 12.7.2 Financials
  • 12.7.3 Depression Emerging Therapy Portfolio
  • 12.7.4 Clinical Development Strategy
  • 12.7.5 Key Drug Candidates
  • 12.7.6 Clinical Trial Programs
  • 12.7.7 Strategic Collaborations
  • 12.7.8 Recent Developments
• 12.8 Emalex Biosciences, Inc.
  • 12.8.1 Overview
  • 12.8.2 Financials
  • 12.8.3 Depression Emerging Therapy Portfolio
  • 12.8.4 Clinical Development Strategy
  • 12.8.5 Key Drug Candidates
  • 12.8.6 Clinical Trial Programs
  • 12.8.7 Strategic Collaborations
  • 12.8.8 Recent Developments
• 12.9 HMNC Holding GmbH
  • 12.9.1 Overview
  • 12.9.2 Financials
  • 12.9.3 Depression Emerging Therapy Portfolio
  • 12.9.4 Clinical Development Strategy
  • 12.9.5 Key Drug Candidates
  • 12.9.6 Clinical Trial Programs
  • 12.9.7 Strategic Collaborations
  • 12.9.8 Recent Developments
• 12.10 Gilgamesh Pharmaceuticals, Inc.
  • 12.10.1 Overview
  • 12.10.2 Financials
  • 12.10.3 Depression Emerging Therapy Portfolio
  • 12.10.4 Clinical Development Strategy
  • 12.10.5 Key Drug Candidates
  • 12.10.6 Clinical Trial Programs
  • 12.10.7 Strategic Collaborations
  • 12.10.8 Recent Developments

13. Future Outlook and Strategic Recommendations

• 13.1 Future Pipeline Evolution
• 13.2 Expected Regulatory Milestones
• 13.3 Commercialization Outlook
• 13.4 Investment Opportunities
• 13.5 Strategic Partnership Opportunities
• 13.6 Competitive Risk Assessment
• 13.7 Long-Term Emerging Therapy Outlook (2025-2045)

14. Research Methodology

• 14.1 Primary Research
• 14.2 Secondary Research
• 14.3 Pipeline Assessment Methodology
• 14.4 Clinical Trial Intelligence Methodology
• 14.5 Forecasting Framework
• 14.6 Data Validation and Triangulation

15. Appendix

• 15.1 Abbreviations
• 15.2 Glossary of Terms
• 15.3 References
• 15.4 List of Tables
• 15.5 List of Figures
• 15.6 Clinical Trial Sources
• 15.7 Regulatory Sources
• 15.8 Company Sources